Sara Pepe

616 total citations
35 papers, 366 citations indexed

About

Sara Pepe is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Sara Pepe has authored 35 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 15 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in Sara Pepe's work include Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Acute Myeloid Leukemia Research (6 papers). Sara Pepe is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Acute Myeloid Leukemia Research (6 papers). Sara Pepe collaborates with scholars based in Italy, United States and Japan. Sara Pepe's co-authors include Emilia Scalzulli, Massimo Breccia, Gioia Colafigli, Simone Polvani, Andrea Galli, Stefano Milani, Márta Korbonits, Donato Iacovazzo, Barbara Stecca and Robin Foà and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sara Pepe

31 papers receiving 362 citations

Peers

Countries citing papers authored by Sara Pepe

Since Specialization

Citations

This map shows the geographic impact of Sara Pepe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Pepe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Pepe more than expected).

Fields of papers citing papers by Sara Pepe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Pepe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Pepe. The network helps show where Sara Pepe may publish in the future.

Co-authorship network of co-authors of Sara Pepe

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Pepe. A scholar is included among the top collaborators of Sara Pepe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Pepe. Sara Pepe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Common brain areas in spatial navigation and visuo-spatial planning: A meta-analysis 2025 ·Neuroscience & Biobehavioral Reviews ·Sara Pepe, (unknown), (unknown), Laura Piccardi	1
2	A New Antibody–Cytokine Construct Targeting Natural Killer Cells: An Immunotherapeutic Approach to Chronic Lymphocytic Leukemia 2025 ·Biomolecules ·(unknown), Mauro Andreotti, Francesca Romana Mauro, (unknown), S Zamboni, Zuleika Michelini, Sara Pepe, Clementina Maria Galluzzo, Roberta Amici, (unknown), (unknown), (unknown), (unknown)	1
3	Robotic bona fide right hepatectomy with ICG-guided detachment technique 2025 ·Surgical Oncology ·Taiga Wakabayashi, Sara Pepe, Muhammad Naeem, Go Wakabayashi	0
4	Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation 2024 ·European Journal Of Haematology ·(unknown), (unknown), Sara Pepe, Emilia Scalzulli, Ida Carmosino, Alessandro Nanni Costa, (unknown), (unknown), Maurizio Martelli, Massimo Breccia	3
5	Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth 2023 ·Pharmacological Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Sara Pepe, (unknown), (unknown), Giuseppe Giannini, Serena Sestini, Lorenzo Borgognoni, Andrea Lapucci, Elena Dreassi, Maurizio Taddei, Fabrizio Manetti, Elena Petricci, Barbara Stecca	16
6	Complication of Gastric Cancer Surgery: A Single Centre Experience 2023 ·In Vivo ·Marta Goglia, Sara Pepe, (unknown), (unknown), Andrea Minervini, (unknown), (unknown), Gaetano Gallo, Giuseppe Nigri, Giovanni Ramacciato, Paolo Aurello	4
7	Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS 2023 ·Frontiers in Oncology ·(unknown), Sara Pepe, Ursula La Rocca, (unknown), Maria Stefania De Propris, Walter Barberi, Anna Paola Iori, S. Martelli, Franco Ruberto, Maurizio Martelli, Alice Di Rocco	2
8	Quinolines and Oxazino-quinoline Derivatives as Small Molecule GLI1 Inhibitors Identified by Virtual Screening 2022 ·ACS Medicinal Chemistry Letters ·Fabrizio Manetti, (unknown), (unknown), Sara Pepe, Elena Cini, Snigdha Singh, Paolo Governa, Samuele Maramai, Giuseppe Giannini, Barbara Stecca, Elena Petricci	7
9	Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group 2022 ·Annals of Hematology ·Sara Pepe, Elena Rossi, Malgorzata Monika Trawinska, Caterina Tatarelli, Ambra Di Veroli, Luca Maurillo, Atelda Romano, Sabrina Leonetti Crescenzi, Tommaso Caravita di Toritto, (unknown), Roberto Latagliata, Emilia Scalzulli, Alessandro Andriani, Valerio De Stefano, Massimo Breccia	3
10	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 2021 ·Annals of Hematology ·Emilia Scalzulli, Giovanni Caocci, Fabio Efficace, (unknown), Gioia Colafigli, (unknown), Sara Pepe, Danilo Alunni Fegatelli, Ida Carmosino, Daniela Diverio, Roberto Latagliata, Giorgio La Nasa, Maurizio Martelli, Robin Foà, Massimo Breccia	3
11	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience 2021 ·Leukemia & lymphoma ·Sara Pepe, Emilia Scalzulli, Gioia Colafigli, (unknown), Marco Mancini, Daniela Diverio, Roberto Latagliata, Maurizio Martelli, Robin Foà, Massimo Breccia	0
12	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients 2020 ·Annals of Hematology ·Emilia Scalzulli, Gioia Colafigli, Roberto Latagliata, Sara Pepe, Daniela Diverio, (unknown), (unknown), Fabio Efficace, Maurizio Martelli, Robin Foà, Massimo Breccia	3
13	E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis 2020 ·Journal of Biological Chemistry ·Valentina Montagnani, (unknown), (unknown), Sara Pepe, Ryan M. Carr, Martín E. Fernández-Zapico, Barbara Stecca	11
14	Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice? 2020 ·Critical Reviews in Oncology/Hematology ·Gioia Colafigli, Emilia Scalzulli, (unknown), Sara Pepe, (unknown), Daniela Diverio, Maurizio Martelli, Robin Foà, Massimo Breccia	13
15	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) 2020 ·Leukemia ·Francesca Romana Mauro, Diana Giannarelli, Clementina Maria Galluzzo, Candida Vitale, Andrea Visentin, (unknown), (unknown), (unknown), Sara Pepe, Marta Coscia, Livio Trentin, Massimo Gentile, Sara Raponi, Alessandra Micozzi, Giuseppe Gentile, Silvia Baroncelli	51
16	ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL 2020 ·Nature Communications ·Silvia Pietrobono, (unknown), (unknown), Fabrizio Manetti, Luciana L. Almada, Sara Pepe, Ryan M. Carr, Brooke D. Paradise, Jann N. Sarkaria, Jaime Davila, Lorenzo Tofani, Ilaria Battisti, Giorgio Arrigoni, Ying Li, Cheng Zhang, Hu Li, Alexander Meves, Martín E. Fernández-Zapico, Barbara Stecca	66
17	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up 2020 ·Leukemia & lymphoma ·Emilia Scalzulli, Gioia Colafigli, Sara Pepe, (unknown), (unknown), Fabio Efficace, Daniela Diverio, Roberto Latagliata, Maurizio Martelli, Robin Foà, Massimo Breccia	3
18	The advantages and risks of ruxolitinib for the treatment of polycythemia vera 2020 ·Expert Review of Hematology ·Gioia Colafigli, Emilia Scalzulli, Sara Pepe, (unknown), Fabio Efficace, Maurizio Martelli, Robin Foà, Massimo Breccia	7
19	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia 2018 ·Expert Review of Hematology ·Francesca Romana Mauro, Maria Caputo, (unknown), Sara Pepe, (unknown), (unknown), Robin Foà	8
20	397 POSTER Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines 2006 ·European Journal of Cancer Supplements ·Tina Cascone, Floriana Morgillo, Gianluca Laus, Sara Pepe, Fortunato Ciardiello	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact